Edition:
United States

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.SS)

600196.SS on Shanghai Stock Exchange

40.23CNY
10:29pm EST
Change (% chg)

¥-0.14 (-0.35%)
Prev Close
¥40.37
Open
¥40.66
Day's High
¥40.75
Day's Low
¥40.13
Volume
4,728,703
Avg. Vol
20,633,059
52-wk High
¥47.58
52-wk Low
¥25.43

Latest Key Developments (Source: Significant Developments)

Shanghai Fosun Pharmaceutical Group unit gets sole license on research of anticarcinogen in China
Tuesday, 13 Feb 2018 11:22pm EST 

Feb 14 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> ::Says its unit signs License and Option Agreement with U.S. company Galaxy Biotech, LLC, to get sole license on research and development of monoclonal antibody for anticarcinogen new drug in China .  Full Article

BRIEF-Shanghai Fosun Pharmaceutical's Unit Signs Agreement To Buy Stake In Foshan Hospital
Monday, 12 Feb 2018 03:49am EST 

Refiles to fix formatting:SAYS UNIT SIGNS AGREEMENT TO BUY ABOUT 21.43 PERCENT STAKE IN A HOSPITAL IN FOSHAN FOR 749.99 MILLION YUAN ($118.51 million).SAYS IT WILL OWN ABOUT 85.43 PERCENT STAKE IN THE HOSPITAL AFTER TRANSACTION.  Full Article

Shanghai Fosun Pharmaceutical Group Co Says‍ Two Units & Shanghai Yunji To Establishment A JV
Thursday, 1 Feb 2018 07:42am EST 

Feb 1 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::TWO UNITS OF CO & SHANGHAI YUNJI ENTER INTO AGREEMENT IN RELATION TO ESTABLISHMENT OF JV CO.‍CHINDEX BEIJING AND CHANCHENG HOSPITAL TO MAKE CASH CONTRIBUTION OF RMB12.5 MILLION & RMB2.5 MILLION RESPECTIVELY TO JV CO​.  Full Article

Shanghai Fosun Pharmaceutical Group unit to invest 27.5 mln yuan to set up pharmaceutical JV
Monday, 22 Jan 2018 12:27am EST 

Jan 22 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Says Shanghai-based investment management unit will invest 27.5 million yuan to set up a Shanghai-based pharmaceutical JV and hold 51 percent stake in the JV.  Full Article

Shanghai Fosun Pharmaceutical Group units receive approval for drug clinical trials
Tuesday, 16 Jan 2018 09:38pm EST 

Jan 17 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Says two Shanghai-based pharmaceutical units received drug clinical trials approval for injection FN-1501, which is mainly used for treatment of leukemia.  Full Article

Shanghai Fosun Plans U.S. JV, To Boost Capital Of Shanghai Biotech Firm
Wednesday, 10 Jan 2018 05:55am EST 

Jan 10 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS UNIT PLANS TO INVEST $25.5 MILLION TO SET UP JV IN THE U.S..SAYS IT PLANS TO BOOST CAPITAL OF SHANGHAI BIOTECH FIRM BY 102 MILLION YUAN ($15.68 million).  Full Article

Shanghai Fosun Pharmaceutical Group signs project investment framework agreement
Friday, 29 Dec 2017 01:15am EST 

Dec 29(Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> ::Says it signed a project investment framework agreement with Xuzhou-based economic and technological development zone management committee.  Full Article

China'S Fosun Plans $3 Billion Of Local Bond Offerings - Bloomberg‍​
Thursday, 28 Dec 2017 10:47am EST 

Dec 28 (Reuters) - :CHINA'S FOSUN PLANS $3 BILLION OF LOCAL BOND OFFERINGS - BLOOMBERG, CITING PEOPLE FAMILIAR WITH THE MATTER ‍​.  Full Article

Shanghai Fosun Pharmaceutical Group unit gets approval for HLX10 clinical trail
Thursday, 21 Dec 2017 12:34am EST 

Dec 21 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> ::Says its Taiwan-based controlling unit gets approval from Ministry of Health and Welfare to launch clinical trail of HLX10(Recombinant Humanized Anti-PD-1 Monoclonal Antibody), which is used for treatment of solid tumor.  Full Article

Shanghai Fosun Pharmaceutical Group's Unit Enters Capital Increase Agreement
Wednesday, 20 Dec 2017 09:44am EST 

Dec 20 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::UNIT ENTERS CAPITAL INCREASE AGREEMENT WITH SHAREHOLDERS OF SHANGHAI HENLIUS, OTHER INVESTORS, SHANGHAI HENLIUS​.FOSUN PHARMA INDUSTRIAL TO ACQUIRE 14.6 MILLION ADDITIONAL SHARES IN SHANGHAI HENLIUS AT RMB22.71 PER SHARE.‍OTHER INVESTORS TO BUY TOTAL OF 40.8 MILLION ADDITIONAL SHARES IN SHANGHAI HENLIUS AT RMB22.71/SHARE, FOR US$140 MILLION​.SHANGHAI HENLIUS TO ISSUE 55.4 MILLION ADDITIONAL SHARES IN CO TO UNIT, OTHER INVESTORS FOR US$190 MILLION​.  Full Article